Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 4/20 | 0.53 |
| ▸ | HTR3A | P46098 | 2/20 | 0.53 |
| ▸ | PARP1 | P09874 | 2/20 | 0.47 |
| ▸ | CDC42 | P60953 | 1/20 | 0.45 |
| ▸ | BRD3 | Q15059 | 7/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5449841 | 0.93 | CACNA1G (0.53) | CACNA1GHTR3APARP1CDC42BRD3 | |
| SCHEMBL5448989 | 0.91 | CACNA1G (0.48) | CACNA1GHTR3APARP1CDC42GAA | |
| SCHEMBL5454063 | 0.87 | ALDH1A1 (0.47) | GAAKDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL5456555 | 0.87 | GAA (0.53) | CACNA1GHTR3APARP1CDC42GAA | |
| SCHEMBL5456602 | 0.85 | BRD3 (0.45) | PARP1CDC42BRD3GAACASP6 | |
| SCHEMBL5460464 | 0.84 | BRD3 (0.44) | PARP1CDC42BRD3GAACASP6 | |
| SCHEMBL5466557 | 0.84 | HTR3A (0.51) | CACNA1GHTR3APARP1CDC42GAA | |
| SCHEMBL5456598 | 0.83 | HTR3A (0.54) | CACNA1GHTR3APARP1CDC42MMP9 | |
| SCHEMBL5458899 | 0.81 | CACNA1G (0.52) | CACNA1GHTR3APARP1ALDH1A1MAPT | |
| SCHEMBL5454081 | 0.81 | GAA (0.52) | CACNA1GHTR3APARP1CDC42GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | MAVS, SARS1, ZC3HAV1 | CACNA1G 4194/4885HTR3A 1237/4885PARP1 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.